Mary Gardner, Chief Executive Officer & Founder
Mary Gardner has more than 25 years’ experience in the life science industry. She is the founder and inventor of DelNova core assets in 2016 and has led the company through its early research phase and into its Series A financing.
Mary has been a mentor for early stage life science companies since 2014, with CONNECT and MATTER; both startup company accelerators in the greater San Diego and Chicago areas, respectively. As former Director of Technology Assessment with Hospira, a Pfizer company (~11 years), she was responsible for the front end of innovation, including supporting business development via the sourcing and evaluation of external new technology and product opportunities to generate future topline growth in healthcare products (pharmaceuticals, drug delivery and medical devices). She is experienced in the healthcare and biotechnology industries, including positions in consulting, process design engineering and project management.
Prior to joining Hospira, Mary led the Business Development office of The Lawson Health Research Institute & London Health Sciences Centre, London, Ontario, where she was responsible for managing the IP portfolio, technology transfer & spin-off companies created from innovations arising from leading Canadian teaching hospitals.
Mary is a Certified Licensing Professional (CLP) and earned an MBA (finance major) from McMaster University, Hamilton and a BEngSc (Chemical & Biochemical) from the University of Western Ontario, London, Canada.
Rebekah Fleming, PhD – Chief Scientist
Dr. Rebekah Fleming is a neurobiologist with broad experience in neuron physiology and neurotransmitter receptor pharmacology. She holds a BA in Physics from Grinnell College and completed multidisciplinary graduate training in the Department of Biomedical Engineering, the Curriculum in Neurobiology, and the Bowles Center for Alcohol Studies at The University of North Carolina at Chapel Hill. After earning her PhD, she moved on to postdoctoral studies in the Department of Psychiatry and Behavioral Sciences at Duke University and at the Durham Veterans Affairs Medical Center. Dr. Fleming received a Career Development Award from the Department of Veterans Affairs. She became an Assistant Professor in the Addiction Division of the Duke Psychiatry Department, successfully competed for research funding, and managed her own basic science research laboratory at the Durham VA. Since transitioning to industry in 2016, she has held several positions as a science and medical writer and consultant. She has helped small pharmaceutical companies to win over $6M in federal grant funding.
Anindita Sarkar – Executive Scientific & Business Leader
Anindita (Ani) Sarkar has a rich experience in commercializing innovations. As a Manager of Springboard Accelerator Program and Innovation Research at CONNECT, she revitalized the program. She engaged with startups from Life Sciences and Tech sectors. She guided them to maximize opportunities to attract investment, talent, and partnerships. Her clients acknowledge her for attracting angel investment of $3M and recruiting ten C-Suite executives in early-stage startups. Prior to that, as a post-doctoral researcher at Scripps Institution of Oceanography, she engaged with multiple teams. She supported the teams in building business cases for their inventions/discoveries. She also engaged with life sciences startups to evaluate market opportunities and competitive product positioning.
Currently, she is supporting the Tech Transfer Office at San Diego State University. She is also a project manager for ThinkingNode, an AI startup. The startup provides a general-purpose AI reasoning computing system to accelerate problem-solving in research and development. Ani received a PhD in Microbiology from Friedrich Schiller University, Germany. M.Sc. in Industrial Microbiology and B.Sc. in Microbiology from Devi Ahilya University, India. She also has a Professional Certificate in Finance from UC San Diego.
Dimas Jiménez, MBA – Chief Financial Officer
Dimas Jiménez, MBA, Chief Financial Officer. Mr. Jiménez received his MBA from Stanford’s Graduate School of Management, his BA from Dartmouth College and has earned the CFA, Chartered Financial Analyst designation. He has worked for Wall Street and life science firms for two decades. Prior to joining StemoniX, he was CFO at Orphagen Pharmaceuticals; VP Finance and Administration at Spinal Modulation; Controller at Pearl Therapeutics, and a Portfolio Manager at JP Morgan. Mr. Jiménez has led the acquisition of two of his companies including the ~$450M purchase of Spinal Modulation by St. Jude Medical.